PMGC Holdings (ELAB) Total Current Liabilities (2022 - 2026)
PMGC Holdings' (ELAB) quarterly Total Current Liabilities came in at $15.3 million in Q2 2026, up 4597.67% year-over-year from $326301.0 in Q2 2025, and up 35.68% quarter-over-quarter from $11.3 million in Q1 2026.
Analysis
PMGC Holdings (ELAB) Total Current Liabilities (2022 - 2026) Analysis & Trends
PMGC Holdings has disclosed Total Current Liabilities across 5 years of filings, most recently posting $15.3 million for Q2 2026.
- In Q2 2026, Total Current Liabilities rose 4597.67% year-over-year to $15.3 million; the TTM figure through Jun 2026 stood at $15.3 million (up 4597.67% YoY), while the FY2025 annual figure was $3.9 million, up 119.12% from the prior year.
- Total Current Liabilities came in at $15.3 million for Q2 2026 at PMGC Holdings, up from $11.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1.6 billion in Q3 2023 to a low of $326301.0 in Q2 2025.
- Average Total Current Liabilities over 5 years is $130.0 million, with a median of $1.9 million recorded in 2024.
- Year-over-year, Total Current Liabilities tumbled 99.87% in 2024 and jumped 4597.67% in 2026.
- Over 5 years, Total Current Liabilities stood at $588272.0 in 2022, then soared by 120.54% to $1.3 million in 2023, then surged by 38.68% to $1.8 million in 2024, then surged by 119.12% to $3.9 million in 2025, then soared by 288.82% to $15.3 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $15.3 million in Q2 2026, $11.3 million in Q1 2026, and $3.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.40 Bn | 192.42 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 180.38 Bn | 177.20 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.43 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 54.02 Bn | 48.88 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 33.28 Bn | 29.97 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.81 Bn | 30.52 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 29.02 Bn | 29.02 Bn | 1.16 Mn | 283.60 Mn |
| 10 | PMGC Holdings | 2.29 Mn | -16.50 Mn | 385,691.00 | 15.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.33 Mn |
| Mar 31, 2026 | 11.30 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 326,301.00 |
| Mar 31, 2025 | 760,268.00 |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 1.64 Bn |
| Dec 31, 2022 | 588,272.00 |